ArticleDiscover oncology2026
Immune microenvironment and its influence on CAR-T treatment outcomes in B-NHL.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
B-cell non-Hodgkin's lymphoma (B-NHL) is a highly heterogeneous tumor. Currently, CAR-T cells have been widely used in the treatment of B-cell lymphomas, with a complete response rate reaching 40%-60%. More and more studies have shown that the immune microenvironment plays an important role in the occurrence and development of B-NHL. However, it is still unclear what role the tumor microenvironment plays in the effect of CAR-T therapy on B-NHL. We analyzed the components of 44 tumor tissue biopsy samples from 36 patients with relapsed or refractory Diffuse large B-cell lymphoma (R/R DLBCL) in our center to explore the immune cell components in the tumor microenvironment that correlated with improved clinical outcomes of CAR-T therapy. The median follow-up time was 8.5 months. We analyzed the impact of various cells on patient survival and identified multiple prognostic protective factors and risk factors. Among them, Treg cells (P < 0.009; HR = 0.32) are a key prognostic protective factor that associated with the efficacy of CAR-T therapy. Further analysis of tumor biopsy samples before and after CAR-T treatment in the same patients revealed that higher Treg cells were associated with the better CAR-T efficacy and were associated with sustained CAR-T persistence. There were more Treg cells in biopsy samples without CAR-T cells remaining after CAR-T treatment. The overall response rate in non-residual CAR-T cells group was 61.5% (n = 8), consisting of CR (30.8%, n = 4), PR (30.8%, n = 4), SD (7.7%, n = 1), and PD (30.8%, n = 4) compared to the residual CAR-T cells group (PR: n = 1, 25%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.